AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®
Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, at the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting. The abstract, #231-OR, is available on the ADA website.